Medical Affairs Reputations: Targeted Therapies in Severe Asthma [Biologics] (US) 2019

Maximum Purchase:
1 unit
Publication Date:
May 2019
Adding to cart… The item has been added

Detailed product-level analysis for benchmarking and improving the performance of medical affairs teams in the US

  • How successful are medical affairs teams in meeting physicians’ needs?
  • What medical affairs services and support do physicians value most?
  • For which severe asthma brands are medical affairs teams delivering services successfully?
  • For which severe asthma brands are medical affairs services falling short and where is there scope for improvement?

Clinicians treating severe asthma need the ongoing support of medical affairs teams to ensure complete knowledge of a product’s clinical value and use. The quality of a medical affairs team’s response and service is critical in supporting prescribing and treatment decisions, so how do front-line physicians rate the service they get and where do they see room for improvement?

This and other key questions are answered in this insightful May 2019 analysis of 5 leading severe asthma brands. Based on the results of an in-depth survey of 100 US-based allergists and pulmonologists, Medical Affairs Reputations (US) Targeted Therapies in Severe Asthma (Biologics) identifies the drivers that build clinician satisfaction and brand loyalty.

Buy Now

Buy and Download this report

Medical affairs teams from leading companies in severe asthma assessed

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis/Roche
  • Regeneron/Sanofi
  • Teva

Leading brands covered in this report

  • Fasenra (benralizumab; AstraZeneca)
  • Cinqair (reslizumab; Teva)
  • Dupixent (dupilumab; Regeneron/Sanofi)
  • Nucala (mepolizumab; GSK)
  • Xolair (omalizumab; Novartis/Roche)

Answering important medical affairs performance questions

  • What underpins the overall rankings of interaction quality for Xolair, Fasenra and Dupixent?
  • What medical affairs services are most used by physicians?
  • How frequently are physicians contacted by medical affairs teams working on Dupixent, Nucala and Xolair?
  • How satisfied are physicians with the information provided on the clinical value of a product in comparison with its competitors?
  • How do physicians prefer to interact and how frequently?
  • Providing unbiased scientific information? Clinical trial updates? Answering medical enquiries? What are the services and attributes most valued by physicians for Cinqair, Dupixent, Nucala and Xolair?

 Exclusive to FirstView, Medical Affairs Reputations surveys reveal, at a brand level, physician satisfaction with the medical affairs services they receive and the key areas where teams can improve their performance

The experience of the physicians surveyed

This detailed analysis is based on a survey of 100 US allergists and pulmonologists with a wealth of experience treating severe asthma. On average they:

  • See 72 severe asthma patients in a typical month
  • Have 19 years in practice
  • Spend 95% of their time on direct patient care

This report gives you...

  • Practical data to understand how allergists and pulmonologists rank the performance of medical affairs teams in severe asthma
  • 32 clear, easy to read charts that provide at-a-glance understanding of the survey findings
  • Actionable and detailed information identifying the specific areas where medical affairs teams can improve their support and engagement with physicians

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other TARGETED THERAPIES IN ASTHMA reports available

Medical Affairs Reputations Europe: Targeted Therapies in Severe Asthma (Biologics)

Market Access Impact US: Targeted Therapies in Severe Asthma (Biologics)

Market Access Impact Europe: Targeted Therapies in Severe Asthma (Biologics)

NPS+ Europe: Targeted Therapies in Severe Asthma (Biologics)

NPS+ Europe: Targeted Therapies in Severe Asthma (Biologics)

Therapy Trends KOL Insight: Targeted Therapies in Asthma

To learn about our cost effective Targeted Therapies in Asthma intelligence package of all reports, please contact us at